低分子肝素在肿瘤治疗中的研究进展

Advances on the Low Molecular Weight Heparin in Oncology Treatment

低分子肝素是一种广泛应用于临床的抗凝剂,近年来,相关研究发现低分子肝素除了抗凝活性外,还具有抗肿瘤的作用。现有研究表明,肝素类分子可能在抑制血管生成、肿瘤细胞生长、迁移和细胞侵袭等方面具有潜在的优势。探究这些分子抑制癌细胞增殖的途径和机制有助于了解肝素类药物的潜在治疗用途。因此,文章通过研究和分析现有的文献和资料,就低分子肝素在肿瘤治疗中的研究进展进行了综述。主要介绍了低分子肝素抑制血管生成、作为肝素酶抑制剂、抑制趋化因子和粘附因子的表达机制和研究现状,同时对肝素类药物与其它药物联合使用、肝素类药物治疗肿瘤临床研究等方面进行综合评价。

Low molecular weight heparin is a widely used anticoagulant in clinical practice.In recent years,studies have revealed that in addition to its anticoagulant activity,low molecular weight heparin also has anti-tumour progressive effects.Available studies suggest that heparin-like molecules may have potential advantages in inhibiting angiogenesis,tumour cell growth,migration and cell invasion.Exploring the pathways and mechanisms by which these molecules inhibit cancer cell proliferation could help to understand the potential therapeutic use of heparin-like drugs.Therefore,the article reviews the research progress of low molecular heparin in tumour therapy by examining and analysing the available literature and data.It mainly introduces the mechanisms and current status of research on the inhibition of angiogenesis by low molecular heparin,as an inhibitor of heparinase,and the inhibition of chemokine and adhesion factor expression,as well as a comprehensive evaluation of the combination of heparin analogues with other drugs and clinical studies of heparin analogues in the treatment of tumours.